

Property values tagged with IC are from the ZIC/VINITI data file

provided by Infocam.

STRUCTURE FILE UPDATES: 29 SEP 2004 HIGHEST RN 754169-63-6

DICTIONARY FILE UPDATES: 29 SEP 2004 HIGHEST RN 754169-63-6

TSOA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/Registryss.html>

=> s CP[DEGM]E[NDEPSI]W[LIT]FC/SOSP

L1 10 CP[DEGM]E[NDEPSI]W[LIT]FC/SOSP

=> FILE CAPLUS

COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:07:22 ON 01 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGERS" FOR DETAILS.

COPYRIGHT
(C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 30 Sep 2004 (20040930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L2 4 L1

=> dup rem 12
PROCESSING COMPLETED FOR 12
L3 2004 DUP REM L2 (0 DUPLICATES REMOVED)

=> d 13 bib ab 1-4

L3 ANSWER 1 OF 4 CAPLUS

COPYRIGHT 2004 ACS on STN

AN 2004:634689 CAPLUS

DN 1411:67846 Binding peptides for the KDR receptor and vascular endothelial growth factor/KDR complex and their use in diagnosis, therapy, and imaging of angiogenesis-related disorders

IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladher, Robert C.; Arbogast, Christopher; Bussat, Philippe; Fan, Hong; Khurana, Sudha; Linder, Karen E.; Marinelli, Edmund R.; Naqashpan, Palanisappa; Nunn, Adrian; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam, Kondareddiar; Dyak Corp., USA; Bracco International B.V.

PA PCT Int. Appl., 470 pp.
SO DT Patent
LA English
LA English
FAN,CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI WO 2004065621	A1	20040505	WO 2003-028787	20030911		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EG, ES, FI, FR, GB, GR, HU, IE, IT, LI, MC, GH, GM, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MK, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TZ, BY, KG, KZ, MD, BG, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CR, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, GM, GA, GN, GS, GW, MU, MR, NE, SN, TD, TG	WO 200307005	A2	2003012	WO 2003-US6731	20030303	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, FR, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MR, MN, NK, MZ, NO, NZ, OH, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TI, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CR, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, GM, GA, GN, GS, GW, MU, MR, NE, SN, TD, TG	WO 2003-382082	A2	200303	WO 2003-US6731	20030303

AB The present invention provides peptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR receptor or vascular endothelial growth factor (VEGF)/KDR complex, which have a variety of uses wherever treating, detecting, isolating, or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated peptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K_D < 1 μ M), and dimer and multimeric constructs comprising these polypeptides. The involvement of VEGF and KDR

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 7557927-15-4

THE JOURNAL OF CLIMATE

Please note that search-term pricing does apply when using the search function.

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

AB KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CG, CI, CM, GA, GR, IE, GW, ML, ME, NE, SN, TD, TG
 EP 1348026 A2 20031001 2001-997103 20011221 R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 200452354 T2 20040505 JP 2002-556612
 PRAI US 2000-747403 A 20001223
 WO 2001-US49534 W 20011221
 OS MARPAT 13790279
 The present invention provides binding moieties for fibrin which have a
 "preferential binding for fibrinogen" or "preferential fibrin and
 "preferential binding for fibrinogen" or "preferential fibrin and

The present invention provides binding moieties for fibrin which have a variety of uses whenever detecting, isolating or antagonizing fibrin, and particularly fibrin as opposed to fibrinogen, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding fibrin and recognizing the form of polyd. Fibrin found in thrombi. In addition, the polypeptides have a slow dissociation rate from fibrin, which improves their ability to form a contrast image at the site of a fibrin clot, making the disclosed binding moieties particularly useful as imaging agents for thrombi. Among examples provided are: screening of phage display libraries using the solid fibrin-derived polypeptide DDE(B) as fibrin target, and scintigraphic imaging of clots in rabbits using ^{99m}Tc-labeled peptides.

LOG IN
COST IN U.S. DOLLARS
FULL ESTIMATED COST

CA SUBSCRIBER PRICE
SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:07:43 ON 01 OCT 2004
END RT
-2.80

5 W [ARNDQEGHILKILRKPSTWVYI] [ANQGLIMP] C [PNQSTI] [ANDQEGIMFIMPSTWVYI] [ES] [PDENOSTV] [LIMQOS
6 TVI] [FWYI] C [FWYI] [PAGNOSTYDEHI] [AILMFFWNONGSTYH] / SQEP
7 L4 0 [W [ARNDQEGHILKILRKPSTWVYI] [ANQGLIMP] C [PNQSTI] [ANDQEGIMFIMPSTWVYI] [ES] [PDENOSTV] [LIMQOS
8 TVI] [FWYI] C [FWYI] [PAGNOSTYDEHI] [AILMFFWNONGSTYH] / SQS

Third round of searching - entire claimed subject matter

FULL ESTIMATED COST 0.21
FILE 'REGISTRY' ENTERED AT 12:01:08 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGERTMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)
Property values tagged with IC are from the ZIC/INITI data file

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

```

=> S 'CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS-TRP-ASP-GLY' /sqsp
L12 2 'CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS' /SQSP
=> S 'CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS' /sqsp
L13 2 'CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS' /SQSP
=> S 'CYS-GLY-TRP-GLX-SER-TRP-LYS-PHE-CYS' /sqsp
L14 2 'CYS-GLY-TRP-GLX-SER-TRP-LYS-PHE-CYS' /SQSP
=> S 'CYS-GLY-TRP-GLX-SER-GLY-LYS-LEU-CYS' /sqsp
L15 2 'CYS-GLY-TRP-GLX-SER-GLY-LYS-LEU-CYS' /SQSP
=> S 'CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS' /sqsp
L16 3 'CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS' /SQSP
=> S 'CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS' /sqsp
L17 2 'CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS' /SQSP
=> S 'CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS' /sqsp
L18 2 'CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS' /SQSP
=> S 'CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS' /sqsp
L19 2 'CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS' /SQSP
=> S 'CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS' /sqsp
L20 2 'CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS' /SQSP
=> S 'CYS-GLY-GLN-GLU-SER-ARG-PHE-CYS' /sqsp
L21 2 'CYS-GLU-GLN-GLU-SER-ARG-PHE-CYS' /SQSP
=> S 'CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS' /sqsp
L22 2 'CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS' /SQSP
=> S 'TRP-MET-MET-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS' /sqsp
L23 1 'TRP-GLU-LEU-GLN-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS' /SQ
SP
=> S 'TRP-MET-MET-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS' /sqsp
L24 1 'TRP-GLU-LEU-GLN-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS' /SQ
SP
=> S 'TRP-GLN-ALA-CYS-PRO-CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS-TRP-ASP-ARG' /sqsp
L25 4 'TRP-GLN-PRO-CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS-TRP-ASP-PRO' /SQ
SP
=> S 'TRP-ALA-PRO-CYS-GLN-GLU-PRO-TRP-LEU-PHE-CYS-TRP-HIS-GLY' /sqsp
L26 2 'TRP-ALA-PRO-CYS-GLN-GLU-PRO-TRP-LEU-PHE-CYS-TRP-HIS-GLY' /SQ
SP
=> S 'PRO-ARG-PRO-CYS-TYR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-LYS-VAL' /sqsp
L27 1 'PRO-ARG-PRO-CYS-TYR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-LYS-VAL' /SQ
SP
=> S 'PRO-ARG-PRO-CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS-GLY-PRO-ARG' /sqsp
L28 1 'PRO-ARG-PRO-CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS-GLY-PRO-ARG' /SQ
SP

```

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:11:42 ON 07 OCT 2004

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:11:42 ON 07 OCT 2004